Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADC189 in Influenza A/B
NCT06342921Phase 3Completed
- Sponsor
- Jiaxing AnDiCon Biotech
- Start
- Dec 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of deunoxavir marboxil in Influenza A virus infection (IAV) and influenza B virus infection (3 arms), sponsored by Jiaxing AnDiCon Biotech. Primary endpoints: Time to remission of all influenza symptoms at 22 days, Time of virus titer turning to negative at 22 days and 1 more. Started Dec 2022; status: completed.
02
Drugs
deunoxavir marboxil
03
Conditions
Influenza A virus infection (IAV)influenza B virus infection
Beyond the preview
Go deeper on NCT06342921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06342921.